By contrast, patients with breast cancer aged over 49 years with the BRCA2 pathogenic variant in exons 12-25 in stage I who underwent RRBM + RRBSO had an almost similar impact on survival compared with those who underwent RRBSO alone. This evidence concerns the gene BRCA2 and breast carcinoma.